Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
patent infringement
Pharma
Halozyme sues Merck over subcutaneous Keytruda
Halozyme alleges in a lawsuit that a subcutaneous formulation of Merck’s popular cancer drug Keytruda infringes 15 of its patents.
Angus Liu
Apr 24, 2025 2:41pm
AstraZeneca inks $1.35B deal for subcutaneous cancer drugs
Mar 17, 2025 10:55am
Merck, Halozyme dig in for patent fight over injectable Keytruda
Mar 6, 2025 11:18am
Arbutus, Genevant expand COVID patent feud with Moderna
Mar 4, 2025 11:49am
Teva agrees with Axsome to keep generic off market until 2038
Feb 10, 2025 11:28am
Roche files patent suit to fend off potential Evrysdi generics
Nov 20, 2024 9:44am
